TW591030B
(en)
|
1997-03-10 |
2004-06-11 |
Janssen Pharmaceutica Nv |
Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
|
US6420555B1
(en)
|
1998-06-16 |
2002-07-16 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Imidazolyl derivatives
|
CA2335435A1
(en)
*
|
1998-06-16 |
1999-12-23 |
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R |
Imidazolyl derivatives
|
IL140721A0
(en)
|
1998-07-06 |
2002-02-10 |
Janssen Pharmaceutica Nv |
Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
|
SK285231B6
(sk)
*
|
1998-07-06 |
2006-09-07 |
Janssen Pharmaceutica N. V. |
Použitie 6-[(imidazol-5-yl)metyl]chinolínovej zlúčeniny na prípravu farmaceutickej kompozície na liečbu artropatie
|
DE69923849T2
(de)
*
|
1998-08-27 |
2006-01-12 |
Pfizer Products Inc., Groton |
Quinolin-2-on-derivate verwendbar als antikrebsmittel
|
AU2477400A
(en)
|
1998-12-08 |
2000-06-26 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6316436B1
(en)
|
1998-12-08 |
2001-11-13 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
PT1140935E
(pt)
|
1998-12-23 |
2003-10-31 |
Janssen Pharmaceutica Nv |
Derivados da quinolina 1,2-ciclizada
|
US6143766A
(en)
*
|
1999-04-16 |
2000-11-07 |
Warner-Lambert Company |
Benzopyranone and quinolone inhibitors of ras farnesyl transferase
|
EP1420015A1
(en)
*
|
1999-06-11 |
2004-05-19 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Imidazolyl derivatives
|
WO2001036395A1
(en)
|
1999-11-15 |
2001-05-25 |
Janssen Pharmaceutica N.V. |
Triazoles as farnesyl transferase inhibitors
|
DE60008206T2
(de)
|
1999-11-30 |
2004-12-02 |
Pfizer Products Inc., Groton |
Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
|
KR20010077400A
(ko)
*
|
2000-02-02 |
2001-08-17 |
성재갑 |
에프타아제 저해제인 엘비42908과 타(他) 항암제와의조합에 의한 항암치료제
|
AU2001233726A1
(en)
*
|
2000-02-04 |
2001-08-14 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitors for treating breast cancer
|
ATE375794T1
(de)
|
2000-02-24 |
2007-11-15 |
Janssen Pharmaceutica Nv |
Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
|
JP2003525246A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
|
WO2001064197A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
|
WO2001064198A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
|
AU2001240658A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with camptothecin compounds
|
JP2003525235A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
抗腫瘍ヌクレオシド誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
|
EP1261374A2
(en)
*
|
2000-02-29 |
2002-12-04 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
|
CA2397349A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Ivan David Horak |
Farnesyl protein transferase inhibitor combinations with an her2 antibody
|
AU2001235496A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
|
CA2397694A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica Inc. |
Farnesyl protein transferase inhibitor combinations
|
EP1263437A2
(en)
*
|
2000-02-29 |
2002-12-11 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with vinca alkaloids
|
CA2397425A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Ivan David Horak |
Farnesyl protein transferase inhibitor combinations with taxane compounds
|
JO2361B1
(en)
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
EP1319661B1
(en)
*
|
2000-09-21 |
2006-03-01 |
Takeda Pharmaceutical Company Limited |
Process for producing a tricyclic fused heterocyclic derivative
|
US7053105B2
(en)
|
2000-09-25 |
2006-05-30 |
Janssen Pharmaceutica, N.V. |
Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
|
AU2002220559A1
(en)
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
|
EP1322644A1
(en)
|
2000-09-25 |
2003-07-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
|
US7173040B2
(en)
|
2000-09-25 |
2007-02-06 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
|
WO2002042296A1
(en)
|
2000-11-21 |
2002-05-30 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting benzoheterocyclic derivatives
|
EP1339407B1
(en)
*
|
2000-11-28 |
2006-04-19 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
|
ES2260316T3
(es)
|
2000-12-27 |
2006-11-01 |
Janssen Pharmaceutica N.V. |
Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa.
|
ATE415161T1
(de)
*
|
2001-02-15 |
2008-12-15 |
Janssen Pharmaceutica Nv |
Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
|
WO2002072574A1
(en)
*
|
2001-03-12 |
2002-09-19 |
Janssen Pharmaceutica N.V. |
Process for the preparation of imidazole compounds
|
ES2323265T3
(es)
*
|
2001-12-19 |
2009-07-10 |
Janssen Pharmaceutica Nv |
Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa.
|
WO2003080058A1
(en)
|
2002-03-22 |
2003-10-02 |
Janssen Pharmaceutica. N.V. |
Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
|
ATE336496T1
(de)
*
|
2002-04-15 |
2006-09-15 |
Janssen Pharmaceutica Nv |
Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20030125268A1
(en)
*
|
2002-08-28 |
2003-07-03 |
Rybak Mary Ellen Margaret |
Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
|
WO2004022097A1
(en)
*
|
2002-09-05 |
2004-03-18 |
Medimmune, Inc. |
Methods of preventing or treating cell malignancies by administering cd2 antagonists
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
KR20110094361A
(ko)
|
2003-04-11 |
2011-08-23 |
메디뮨 엘엘씨 |
재조합 il9 항체 및 그의 용도
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
EP2272566A3
(en)
|
2003-08-18 |
2013-01-02 |
MedImmune, LLC |
Humanisation of antibodies
|
FR2860235A1
(fr)
*
|
2003-09-29 |
2005-04-01 |
Yang Ji Chemical Company Ltd |
Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20050272068A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
UCH-L1 expression and cancer therapy
|
EP1732549A4
(en)
*
|
2004-03-18 |
2009-11-11 |
Brigham & Womens Hospital |
METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
WO2005089504A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
WO2005089502A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20060121042A1
(en)
|
2004-10-27 |
2006-06-08 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
DK1815247T3
(da)
|
2004-11-05 |
2013-03-11 |
Janssen Pharmaceutica Nv |
Terapeutisk anvendelse af farnesyltransferaseinhibitorer og fremgangsmåder til overvågning af deres effektivitet
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
JP5153613B2
(ja)
|
2005-03-18 |
2013-02-27 |
メディミューン,エルエルシー |
抗体のフレームワーク・シャッフル
|
US20060281769A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
|
US20060281755A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
|
US20060281788A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US20070004660A1
(en)
*
|
2005-06-10 |
2007-01-04 |
Baumann Christian A |
Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
|
WO2007002543A2
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
CA2634598A1
(en)
|
2005-12-23 |
2007-07-05 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
DK2021335T3
(da)
*
|
2006-04-20 |
2011-09-05 |
Janssen Pharmaceutica Nv |
Heterocykliske forbindelser som C-FMS-kinasehæmmere
|
MX2008013530A
(es)
|
2006-04-20 |
2009-01-14 |
Janssen Pharmaceutica Nv |
Inhibidores de c-fms cinasa.
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
MY162024A
(en)
|
2006-08-28 |
2017-05-31 |
La Jolla Inst Allergy & Immunology |
Antagonistic human light-specific human monoclonal antibodies
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
JO3240B1
(ar)
*
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
KR101686247B1
(ko)
|
2007-10-31 |
2016-12-14 |
메디뮨 엘엘씨 |
단백질 스캐폴드
|
US7932036B1
(en)
|
2008-03-12 |
2011-04-26 |
Veridex, Llc |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
|
US8232402B2
(en)
*
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
DE102008022221A1
(de)
*
|
2008-05-06 |
2009-11-12 |
Universität des Saarlandes |
Inhibitoren der humanen Aldosteronsynthase CYP11B2
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
EP2370436A1
(en)
*
|
2008-11-13 |
2011-10-05 |
Link Medicine Corporation |
Azaquinolinone derivatives and uses thereof
|
EP2947073B1
(en)
*
|
2009-10-22 |
2019-04-03 |
Fibrotech Therapeutics Pty Ltd |
Fused ring analogues of anti-fibrotic agents
|
US8541404B2
(en)
*
|
2009-11-09 |
2013-09-24 |
Elexopharm Gmbh |
Inhibitors of the human aldosterone synthase CYP11B2
|
JP6034784B2
(ja)
|
2010-07-28 |
2016-11-30 |
ジャンセン ダイアグノスティックス,エルエルシー |
ファルネシルトランスフェラーゼ阻害剤による治療に対する急性白血病応答を判定するための方法
|
DK2668210T3
(da)
|
2011-01-26 |
2020-08-24 |
Celldex Therapeutics Inc |
Anti-kit antistoffer og anvendelser deraf
|
EP2877493B1
(en)
|
2012-07-25 |
2018-03-21 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
EP2882757B1
(en)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Process for the preparation of heterocyclic ester derivatives
|
EP2906598A1
(en)
|
2012-10-09 |
2015-08-19 |
Igenica Biotherapeutics, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
WO2014056567A1
(de)
*
|
2012-10-11 |
2014-04-17 |
Merck Patent Gmbh |
Materialien für organische elektrolumineszenzvorrichtungen
|
ES2891755T3
(es)
|
2013-06-06 |
2022-01-31 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
KR102362630B1
(ko)
|
2013-08-26 |
2022-02-15 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
시알릴-루이스 a에 대한 사람 항체 코드화 핵산
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
HUE055189T2
(hu)
|
2014-06-04 |
2021-11-29 |
Biontech Res And Development Inc |
Humán monoklonális antitestek a GD2 ganglioziddal ellen
|
ES2934940T3
(es)
|
2014-12-11 |
2023-02-28 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
MX2017011194A
(es)
|
2015-03-03 |
2018-04-10 |
Kymab Ltd |
Anticuerpos, usos y métodos.
|
KR20210048600A
(ko)
|
2015-08-17 |
2021-05-03 |
쿠라 온콜로지, 인크. |
파르네실전달효소 억제제를 이용하여 암환자를 치료하는 방법
|
WO2017096017A1
(en)
|
2015-12-02 |
2017-06-08 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
JP7090545B2
(ja)
|
2015-12-02 |
2022-06-24 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
|
AU2017353838A1
(en)
|
2016-11-03 |
2019-05-23 |
Kura Oncology, Inc. |
Farnesyltransferase inhibitors for use in methods of treating cancer
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
KR20200015602A
(ko)
|
2017-05-31 |
2020-02-12 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
CN111051346A
(zh)
|
2017-05-31 |
2020-04-21 |
斯特库伯株式会社 |
使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
|
WO2018226671A1
(en)
|
2017-06-06 |
2018-12-13 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
CN111630069A
(zh)
|
2017-10-13 |
2020-09-04 |
勃林格殷格翰国际有限公司 |
针对Thomsen-nouvelle(Tn)抗原的人抗体
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
MX2021000786A
(es)
|
2018-07-20 |
2021-06-15 |
Pf Medicament |
Receptor para supresor de ig del dominio v de activación de células t (vista).
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|